• Forecasts profit attributable to owners of RMB 5.9-6.2 billion for the six months ended June 30, 2026, up from about RMB 2.55 billion.
• Expects to recognize USD 840 million of a USD 1.2 billion AstraZeneca upfront payment as Q2 2026 license fee income, about RMB 5.74 billion.
• Finished drugs sales revenue rose about 10% year over year in the period, excluding the license fee income impact.
• Interim results for the period are scheduled for release on Aug. 20, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260727-12257417), on July 27, 2026, and is solely responsible for the information contained therein.